NYSE:EVHEvolent Health Stock Price, Forecast & News

Evolent Health's stock was trading at $6.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EVH stock has increased by 88.7% and is now trading at $13.06.
View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Evolent Health.

Evolent Health is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Evolent Health.

Evolent Health Inc (NYSE:EVH) posted its quarterly earnings results on Tuesday, August, 4th. The technology company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.14. Evolent Health had a negative return on equity of 4.29% and a negative net margin of 53.56%.
View Evolent Health's earnings history.

Evolent Health updated its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $995M - 1.035 billion, compared to the consensus revenue estimate of $977.85 million.

11 Wall Street analysts have issued 1-year target prices for Evolent Health's shares. Their forecasts range from $8.00 to $20.00. On average, they anticipate Evolent Health's stock price to reach $13.56 in the next twelve months. This suggests a possible upside of 3.8% from the stock's current price.
View analysts' price targets for Evolent Health.

News coverage about EVH stock has trended extremely negative on Sunday, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Evolent Health earned a news sentiment score of -4.8 on InfoTrie's scale. They also assigned news coverage about the technology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Evolent Health.

Some companies that are related to Evolent Health include Premier (PINC), Mantech International (MANT), R1 RCM (RCM), Franklin Covey (FC), Jupai (JP), PHI Group (PHIL) and Rainmaker Systems (VCTL).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include CA (CA), BlackRock (BLK), Universal Insurance (UVE), Endologix (ELGX), Chipotle Mexican Grill (CMG), Energy Transfer LP Unit (ET), Netflix (NFLX), Micron Technology (MU), Advanced Micro Devices (AMD) and Aegean Marine Petroleum Network (ANW).

(EVH) raised $150 million in an initial public offering on Friday, June 5th 2015. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."

Evolent Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (1.36%), DC Investments Management LLC (1.36%), Profit Investment Management LLC (0.24%), Swiss National Bank (0.20%), New York State Common Retirement Fund (0.14%) and Paradigm Capital Management Inc. NY (0.07%). Company insiders that own Evolent Health stock include Doug S Aron, Frank J Williams, Jonathan Weinberg, Kenneth A Samet, Lydia Stone, Michael D'amato, Seth Blackley and Thomas Peterson III.
View institutional ownership trends for Evolent Health.

EVH stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Peregrine Capital Management LLC, and US Bancorp DE.
View insider buying and selling activity for Evolent Health.

EVH stock was purchased by a variety of institutional investors in the last quarter, including DC Investments Management LLC, Profit Investment Management LLC, Paradigm Capital Management Inc. NY, New York State Common Retirement Fund, Swiss National Bank, WoodTrust Financial Corp, SeaCrest Wealth Management LLC, and ProShare Advisors LLC. Company insiders that have bought Evolent Health stock in the last two years include Doug S Aron, Kenneth A Samet, Michael D'amato, and Seth Blackley.
View insider buying and selling activity for Evolent Health.

Shares of EVH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EVH stock can currently be purchased for approximately $13.06.

Evolent Health has a market capitalization of $1.12 billion and generates $846.38 million in revenue each year. The technology company earns $-301,970,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Evolent Health employs 3,400 workers across the globe.

The official website for Evolent Health is www.evolenthealth.com.

Evolent Health's mailing address is 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203. The technology company can be reached via phone at 571-389-6000.